Advm News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Advm. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Advm Today - Breaking & Trending Today

Adverum Biotechnologies (NASDAQ:ADVM) Research Coverage Started at HC Wainwright

HC Wainwright initiated coverage on shares of Adverum Biotechnologies (NASDAQ:ADVM – Free Report) in a report issued on Tuesday morning, Marketbeat reports. The brokerage issued a buy rating and a $30.00 target price on the biotechnology company’s stock. HC Wainwright also issued estimates for Adverum Biotechnologies’ Q1 2024 earnings at ($1.23) EPS, Q2 2024 earnings […] ....

James Paul Scopa , Adverum Biotechnologie , Newtyn Management , Citigroup Inc , Capital Management , Adverum Biotechnologies Inc , Adverum Biotechnologies Company Profile , Adverum Biotechnologies , Free Report , Moderate Buy , Get Free Report , Director James Paul Scopa , Asset Management , Apexium Financial , Adverum Biotechnologies Daily , Nasdaq Advm , Initiated Coverage , Hc Wainwright ,

Adverum Biotechnologies (NASDAQ:ADVM) Price Target Lowered to $22.00 at Mizuho

Adverum Biotechnologies (NASDAQ:ADVM – Free Report) had its target price trimmed by Mizuho from $40.00 to $22.00 in a report issued on Monday morning, Benzinga reports. The brokerage currently has a buy rating on the biotechnology company’s stock. A number of other research analysts also recently issued reports on the company. StockNews.com raised Adverum Biotechnologies […] ....

James Paul Scopa , Adverum Biotechnologies Company Profile , Capital Management , Adverum Biotechnologies Inc , Newtyn Management , Securities Exchange Commission , Citigroup Inc , Adverum Biotechnologies , Free Report , Moderate Buy , Get Free Report , Director James Paul Scopa , Exchange Commission , Asset Management , Apexium Financial , Adverum Biotechnologies Daily , Nasdaq Advm , Lower Price Target ,

Adverum Biotechnologies (NASDAQ:ADVM) Upgraded at StockNews.com

StockNews.com upgraded shares of Adverum Biotechnologies (NASDAQ:ADVM – Free Report) from a sell rating to a hold rating in a research note issued to investors on Friday. A number of other equities analysts have also recently commented on ADVM. Mizuho lifted their price target on Adverum Biotechnologies from $20.00 to $40.00 and gave the stock […] ....

James Paul Scopa , Cantor Fitzgerald , Adverum Biotechnologies Company Profile , Adverum Biotechnologies Inc , Geode Capital Management , Topco Ltd , York Mellon Corp , Adverum Biotechnologies , Free Report , Get Free Report , Director James Paul Scopa , New York Mellon Corp , Capital Management , Monaco Asset Management , Asset Management , Adverum Biotechnologies Daily , Nasdaq Advm , Stocknews Com ,

Contrasting Adverum Biotechnologies (NASDAQ:ADVM) and Agenus (NASDAQ:AGEN)

Adverum Biotechnologies (NASDAQ:ADVM – Get Free Report) and Agenus (NASDAQ:AGEN – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability. Profitability This table compares Adverum Biotechnologies and Agenus’ […] ....

United States , Redwood City , Gensight Biologics , Merck Sharpe Dohme , Adverum Biotechnologies Inc , Gilead Sciences Inc , Agenus Inc , Betta Pharmaceuticals Co Ltd Incyte Corporation , Avalanche Biotechnologies Inc , Bristol Myers Squibb Company , Virovek Inc , Antigenics Inc , University Of California , Adverum Biotechnologies , Get Free Report , Given Agenu , Lexeo Therapeutics , Avalanche Biotechnologies , Retrocyte Display , Incyte Corporation , Merck Sharpe , Gilead Sciences , Adverum Biotechnologies Daily , Nasdaq Advm , Stock Comparison , Stock Analysis ,